Technology | September 09, 2008

Abbott Features XIENCE V Drug-Eluting Stent

Abbott Vascular will showcase its XIENCE V Everolimus Eluting Coronary Stent System, indicated for the treatment of coronary artery disease.

According to the company, the FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS).

Related Content

News | February 11, 2010
February 11, 2010 – former president Bill Clinton received two coronary stents today after being admitted to the...
News | April 08, 2008
April 8, 2008 – Students at Ivy Tech Community College in Bloomington, IN, will be the first in the nation to be offe
News | April 07, 2008
April 8, 2008 - The government on Monday said it would raise payments next year to insurers that provide healthcare c
News | March 16, 2008
March 17, 2008 - The American public believes doctors and physicians would do a good job running hospitals in their c
News | December 13, 2007
December 14, 2007 – Hologic Inc.
News | October 28, 2007
October 29, 2007 - Lake Hospital System today said it has invested in VaproSure Room Sterilizer technology, giving th

Dr. Gerety, a radiologist at St. Mary's Hospital, is sitting at the AMICAS PACS workstation.

Case Study | October 18, 2007
“St.

A traditional palliative treatment with two treatment fields aimed from the

Case Study | October 18, 2007
Each year, some 4,000 patients receive treatment at The Ottawa Hospital Cancer Center (TOHCC).

Dedicated Bustleton staff enjoy the benefits of the PACS and other advanced healthcare IT technology.

Case Study | October 18, 2007
Maybe it’s his personal resolve or dedication to a family business.
Overlay Init